...
首页> 外文期刊>Human Pathology >Adenoid cystic carcinomas of the breast have low Topo IIalpha expression but frequently overexpress EGFR protein without EGFR gene amplification.
【24h】

Adenoid cystic carcinomas of the breast have low Topo IIalpha expression but frequently overexpress EGFR protein without EGFR gene amplification.

机译:乳腺腺样囊性癌的Topo IIalpha表达低,但经常过度表达EGFR蛋白而没有EGFR基因扩增。

获取原文
获取原文并翻译 | 示例
           

摘要

Adenoid cystic carcinoma of the breast is a rare subtype of breast cancer with basal-like features. Published studies on breast adenoid cystic carcinoma are limited, resulting in relatively scarce information on the value of predictive tumor markers. We studied 20 primary cases of adenoid cystic carcinoma of the breast for expression of estrogen receptor, progesterone receptor, androgen receptor, epidermal growth factor receptor, HER-2eu, and topoisomerase IIalpha using immunohistochemistry and fluorescent in situ hybridization methods. Estrogen and progesterone receptor expression were detected in 1 case each. All tumors were uniformly negative for Her-2eu expression. Androgen receptor and topoisomerase IIalpha expression were weakly positive in three cases and 7 cases, respectively. Epidermal growth factor receptor overexpression was detected in 13 cases (65% of all cases). Amplification of TOP2A or HER-2eu gene was not detected in any of the cases. Our study shows that the majority of adenoid cystic carcinomas of the breast do not overexpress Her-2eu, topoisomerase IIalpha, or estrogen receptor, and thus, they are unlikely to respond to therapies targeting these proteins. However, these tumors frequently over-express epidermal growth factor receptor, indicating a potential benefit from anti-epidermal growth factor receptor therapy for patients with advanced adenoid cystic carcinomas of the breast.
机译:乳腺腺样囊性癌是一种罕见的乳腺癌,具有基底样特征。关于乳腺腺样囊性癌的已发表研究是有限的,导致关于预测性肿瘤标志物的价值的信息相对匮乏。我们使用免疫组织化学和荧光原位杂交方法研究了20例乳腺腺样囊性癌的雌激素受体,孕激素受体,雄激素受体,表皮生长因子受体,HER-2 / neu和拓扑异构酶IIalpha的表达。分别在1例中检测到雌激素和孕激素受体的表达。所有肿瘤均一致地阴性表达Her-2 / neu。雄激素受体和拓扑异构酶IIalpha表达分别为3例和7例弱阳性。 13例(占所有病例的65%)检测到表皮生长因子受体过表达。在任何情况下均未检测到TOP2A或HER-2 / neu基因的扩增。我们的研究表明,大多数乳腺腺样囊性癌不会过表达Her-2 / neu,拓扑异构酶IIalpha或雌激素受体,因此,它们不太可能对靶向这些蛋白的疗法产生反应。但是,这些肿瘤经常过度表达表皮生长因子受体,表明抗表皮生长因子受体治疗对乳腺癌晚期腺样囊性癌的潜在益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号